Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 13589

1.

POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen.

Cohen AL, Factor RE, Mooney K, Salama ME, Wade M, Serpico V, Ostrander E, Nelson E, Porretta J, Matsen C, Bernard P, Boucher K, Neumayer L.

Breast. 2016 Dec 1;31:219-223. doi: 10.1016/j.breast.2016.11.016. [Epub ahead of print]

PMID:
27915204
2.

Feature of amenorrhea in postoperative tamoxifen users with breast cancer.

Kim H, Han W, Ku SY, Suh CS, Kim SH, Choi YM.

J Gynecol Oncol. 2016 Oct 27:e10. doi: 10.3802/jgo.2017.28.e10. [Epub ahead of print]

3.

Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.

Sanz A, Del Valle ML.

N Engl J Med. 2016 Oct 20;375(16):1590-1591. doi: 10.1056/NEJMc1610719. No abstract available.

PMID:
27797309
4.

Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.

[No authors listed]

N Engl J Med. 2016 Oct 20;375(16):1590-1591. No abstract available.

PMID:
27797308
5.

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.

Hong JH, Ha KS, Jung YH, Won HS, An HJ, Lee GJ, Kang D, Park JC, Park S, Byun JH, Suh YJ, Kim JS, Park WC, Jung SS, Park IY, Chung SM, Woo IS.

Cancer Res Treat. 2016 Oct;48(4):1389-1398.

7.

Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.

Due SL, Watson DI, Bastian I, Ding GQ, Sukocheva OA, Astill DS, Vat L, Hussey DJ.

Surg Oncol. 2016 Sep;25(3):269-77. doi: 10.1016/j.suronc.2016.05.029.

PMID:
27566033
8.

Increasing Precision in Adjuvant Therapy for Breast Cancer.

Hudis CA, Dickler M.

N Engl J Med. 2016 Aug 25;375(8):790-1. doi: 10.1056/NEJMe1607947. No abstract available.

PMID:
27557306
9.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.

Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7.

PMID:
27484880
10.

Decreased miR-124-3p Expression Prompted Breast Cancer Cell Progression Mainly by Targeting Beclin-1.

Zhang F, Wang B, Long H, Yu J, Li F, Hou H, Yang Q.

Clin Lab. 2016;62(6):1139-45.

PMID:
27468577
11.

Development of Novel Polymer-Lipid Hybrid Nanoparticles of Tamoxifen: In Vitro and In Vivo Evaluation.

Varthya M, Pawar H, Singh C, Dora CP, Jena SK, Suresh S.

J Nanosci Nanotechnol. 2016 Jan;16(1):253-60.

PMID:
27398452
12.

Leg cramps associated with tamoxifen use--possible mechanism and treatment recommendations.

Karatas F, Sahin S, Babacan T, Akin S, Sever AR, Altundag K.

J BUON. 2016 Mar-Apr;21(2):520. No abstract available.

PMID:
27273968
13.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR.

N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700.

14.

[Male breast cancer].

Mattson J, Vehmanen L.

Duodecim. 2016;132(7):627-31. Review. Finnish.

PMID:
27188086
15.

Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.

Santorelli ML, Hirshfield KM, Steinberg MB, Rhoads GG, Lin Y, Demissie K.

Ann Epidemiol. 2016 Jun;26(6):436-40. doi: 10.1016/j.annepidem.2016.04.004.

PMID:
27157863
16.

Placental Kisspeptins Differentially Modulate Vital Parameters of Estrogen Receptor-Positive and -Negative Breast Cancer Cells.

Rasoulzadeh Z, Ghods R, Kazemi T, Mirzadegan E, Ghaffari-Tabrizi-Wizsy N, Rezania S, Kazemnejad S, Arefi S, Ghasemi J, Vafaei S, Mahmoudi AR, Zarnani AH.

PLoS One. 2016 Apr 21;11(4):e0153684. doi: 10.1371/journal.pone.0153684.

17.

Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer.

Choi MY, Lee SK, Lee JE, Park HS, Lim ST, Jung Y, Ko BK, Nam SJ; Korean Breast Cancer Society..

Medicine (Baltimore). 2016 Apr;95(16):e3299. doi: 10.1097/MD.0000000000003299.

18.

Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer.

Sendur MA, Aksoy S, Ozdemir NY, Zengin N, Yazici O, Sever AR, Altundag K.

J BUON. 2016 Jan-Feb;21(1):27-34.

PMID:
27061527
19.

Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients.

Jeon SJ, Lee JI, Jeon MJ, Lee M.

Medicine (Baltimore). 2016 Apr;95(14):e3301. doi: 10.1097/MD.0000000000003301.

20.

The Author's Response: Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use.

Kim SI, Lim MC, Lee ES.

J Korean Med Sci. 2016 Apr;31(4):647. doi: 10.3346/jkms.2016.31.4.647. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center